<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166790</url>
  </required_header>
  <id_info>
    <org_study_id>9461700666</org_study_id>
    <secondary_id>NSC 94-2314-B-002-221</secondary_id>
    <nct_id>NCT00166790</nct_id>
  </id_info>
  <brief_title>Detection of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease</brief_title>
  <official_title>Detection of Minimal Amount of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      We will try to use the novel analytical technique -Dual Polarisation Interferometry (DPI),to&#xD;
      achieve detection the minimal amount of the human chorionic gonadotropin for early detection&#xD;
      and strict monitor of the GTD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1 Gestational trophoblastic disease (GTD) consists of a spectrum of disorders that are&#xD;
      characterized by an abnormal proliferation of trophoblastic tissue. They include hydatidiform&#xD;
      mole, invasive mole, choriocarcinoma and placental site trophoblastic tumor (PSTT). The&#xD;
      incidence of molar pregnancies in Asian countries is 7 to 10 times greater than the reported&#xD;
      incidence in Europe or North America. Although previously a lethal disease, GTD is considered&#xD;
      today the most curable gynecologic cancer. This progress can be attributed to an available&#xD;
      tumor markerhuman chorionic gonadotropin (hCG), chemosensitivity, and the incorporation of&#xD;
      aggressive multimodality therapy. However, a delay in the diagnosis may increase the&#xD;
      patient's risk of developing malignant GTN and adversely affect response to treatment, and&#xD;
      therefore the prompt identification of GTN is important. Approximately 20% of patients will&#xD;
      develop malignant sequelae requiring administration of chemotherapy after evacuation of&#xD;
      hydatidiform moles. The overall cure rate for patients with nonmetastatic disease and&#xD;
      low-risk metastatic disease is nearly 100% .When chemotherapy is given for an additional 1-2&#xD;
      cycles after the first normal hCG value, recurrence rates are less than 5%. In contrast, in&#xD;
      high risk metastatic disease, chemotherapy is continued until hCG values have normalized,&#xD;
      followed by at least two or three courses of maintenance chemotherapy in the hopes of&#xD;
      eradicating all viable tumors. Despite the use of sensitive hCG assays and maintenance&#xD;
      chemotherapy, up to 13% of patients with high-risk disease will develop recurrence after&#xD;
      achieving an initial remission. Conventionally, serial quantitative serum hCG determinations&#xD;
      should be performed using commercially available assays capable of detecting Î²-hCG to&#xD;
      baseline values(&lt;5 mIU/ml). However, the amount of hCG produced correlates with tumor volume&#xD;
      so that a serum hCG of 5 mIU/mL corresponds to approximately 104 to 105 viable tumor cells.&#xD;
      Therefore, detection of minimal amount of human chorionic gonadotropin (&lt;5 mIU/ml) is&#xD;
      crucial, it could help to early detect the GTD and strictly monitor the residual activity of&#xD;
      the tumor after chemotherapy.&#xD;
&#xD;
      Dual Polarisation Interferometry (DPI) is an analytical technique used to understand the&#xD;
      real-time structure and behaviour of a wide range of molecular systems and interactions&#xD;
      through quantitative measurement including molecular size, density and mass. DPI has been&#xD;
      successful across a range of applications, including proteins,lipids, nucleic acids, lectins,&#xD;
      surfactants, polymers, interfacial studies, surface characterisation and nanotechnology.&#xD;
&#xD;
      Herein, we are trying to use the novel analytical technique -Dual Polarisation Interferometry&#xD;
      (DPI),to achieve detection the minimal amount of the human chorionic gonadotropin for early&#xD;
      detection and strict monitor of the GTD. Under this circumstance, maintenance chemotherapy is&#xD;
      continued until hCG values is totally undetectable, in the hopes of eradicating all viable&#xD;
      tumors. Besides this method could be more precise in sensitivity and specificity to avoid the&#xD;
      false positive result which could led to unnecessary chemotherapy or surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>HCG LEVEL</measure>
    <time_frame>REMISSION</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Trophoblastic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy agents</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>suction curettage</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        GTD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hydatidiform Mole&#xD;
&#xD;
          -  Choriocarcinoma&#xD;
&#xD;
          -  Gestational Trophoblastic Neoplasms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruey-Jien Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan university Hospital, Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruey-Jien Chen, MD, PhD</last_name>
    <phone>886-2 -2312-3456</phone>
    <phone_ext>5158</phone_ext>
    <email>rjchen@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital Department of Obstetrics and Gynecology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruey-Jien Chen, MD, PhD</last_name>
      <phone>886-2-2312-3456</phone>
      <phone_ext>5158</phone_ext>
      <email>rjchen@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Ruey-Jien Chen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lichtenberg ES. Gestational trophoblastic tumor after medical abortion. Obstet Gynecol. 2003 May;101(5 Pt 2):1137-9.</citation>
    <PMID>12738129</PMID>
  </reference>
  <reference>
    <citation>Behtash N, Ghaemmaghami F, Honar H, Riazi K, Nori A, Modares M, Mousavi A. Is normal beta-hCG regression curve helpful in the diagnosis of persistent trophoblastic disease? Int J Gynecol Cancer. 2004 Sep-Oct;14(5):980-3.</citation>
    <PMID>15361212</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Chorionic Gonadotropin</keyword>
  <keyword>Dual Polarization Interferometry,</keyword>
  <keyword>Gestational Trophoblastic Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

